经治新生血管性年龄相关性黄斑变性患者对侧眼发生脉络膜新生血管后的抗血管内皮生长因子治疗结局
这项回顾性单中心病例系列纳入264例双侧新生血管性年龄相关性黄斑变性(nvAMD)患者,比较先发病眼与后发病对侧眼在转化时的视力及等效随访约20个月后的视力。对侧眼在转化时视力优于先发病眼(20/50 vs 20/90,相差14个字母,95%CI 10-17,P<.001),等效随访后仍优于先发病眼(20/50 vs 20/70,相差8个字母,95%CI 4-11,P<.001),两组抗VEGF注射次数无差异(9.7 vs 10.0次)。作者认为对侧眼可能因更早发现和更早治疗而获得更好视力。
要点
- 对侧眼转化时平均视力20/50,优于先发病眼的20/90,相差14个字母(P<.001)。
- 等效随访约20个月后,对侧眼平均视力20/50仍优于先发病眼的20/70,相差8个字母(P<.001)。
- 对侧眼与先发病眼平均抗VEGF注射次数分别为9.7次与10.0次,未检出差异。
核心结论
- 这项回顾性研究提示,经治nvAMD患者的对侧眼在等效随访后可能获得比先发病眼更好的视力。
- 作者认为这可能是因为对侧眼的脉络膜新生血管(CNV)在更好视力水平时被更早发现并治疗,但尚不清楚频繁门诊、视力测量或光学相干断层扫描(OCT)检查中哪项促成在更好视力水平检出。
研究设计与样本
- 回顾性单中心病例系列,数据来自一家私立玻璃体视网膜诊所,收集2015年10月1日至2016年10月1日期间接受双侧nvAMD治疗且能确定先发病眼与对侧眼转化为nvAMD日期的所有患者数据(n=1600)。
- 按机构方案,每次门诊就诊时筛查对侧眼新发CNV;排除可能造成显著不对称视力丧失的疾病患者。
- 共264例患者符合纳入标准,其中197例(74.6%)为女性,253例(95.8%)为白人;先发病眼转化为nvAMD时平均(SD)年龄79.1(8.2)岁,对侧眼转化时80.6(8.2)岁。
主要发现
- 对侧眼转化时平均视力20/50(0.40 logMAR),先发病眼为20/90(0.67 logMAR),相差14个字母(0.27 logMAR),95%CI 10-17(0.20-0.34),P<.001。
- 在约20个月的等效转化后随访中,先发病眼平均视力20/70(0.56 logMAR),对侧眼20/50(0.40 logMAR),相差8个字母(0.15 logMAR),95%CI 4-11(0.08-0.22),P<.001。
- 对侧眼与先发病眼平均抗血管内皮生长因子注射次数分别为9.7次与10.0次,未检出差异。
关键数值与推荐
- 对侧眼转化时平均视力20/50(0.40 logMAR)vs 先发病眼20/90(0.67 logMAR),对侧眼较先发病眼高14个字母(95%CI 10-17,P<.001)。
- 等效随访约20个月后,对侧眼平均视力20/50(0.40 logMAR)vs 先发病眼20/70(0.56 logMAR),对侧眼较先发病眼高8个字母(95%CI 4-11,P<.001)。
- 对侧眼平均抗VEGF注射9.7次 vs 先发病眼10.0次,原文未报告差异的统计学检验结果。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文自述为回顾性研究。
- 原文自述为单中心病例系列。
- 原文指出尚不清楚频繁门诊就诊、视力测量或OCT检查中哪项促成对侧眼在更好视力水平被检出。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Neovascular age-related macular degeneration (nvAMD) is a leading cause of vision loss. The optimal screening protocol to detect choroidal neovascularization (CNV) in fellow eyes of patients undergoing treatment for unilateral CNV has not been determined. OBJECTIVE: To compare the visual outcomes of eyes with established, active nvAMD in index eyes with outcomes of fellow eyes that subsequently developed CNV during the management protocol. DESIGN, SETTING, AND PARTICIPANTS: In this retrospective single-center case series conducted at a private vitreoretinal practice, data were collected for all patients treated for bilateral nvAMD between October 1, 2015, and October 1, 2016, for whom we could determine the date of index eye and fellow eye conversion to nvAMD (n = 1600). Per institutional protocol, patients were screened for new CNV in the fellow eye at every office visit. Patients were excluded if they had a condition that could result in marked asymmetric vision loss. EXPOSURES: Development of nvAMD. MAIN OUTCOMES AND MEASURES: Visual acuity (VA) at the time of diagnosis of nvAMD and at equivalent time points following conversion to nvAMD for both index eyes and fellow eyes. RESULTS: A total of 264 patients met the inclusion criteria; 197 (74.6%) were women and 253 (95.8%) were white, and the mean (SD) age was 79.1 (8.2) years at time of index eye conversion to nvAMD and 80.6 (8.2) years at time of fellow eye conversion to nvAMD. Fellow eyes presented with better VA (mean VA, 20/50 [0.40 logMAR]) compared with index eyes (mean VA, 20/90 [0.67 logMAR]) at the time of conversion (difference, 14 letters [0.27 logMAR]; 95% CI, 10-17 [0.20-0.34]; P < .001). Index eyes did not achieve the same level of VA as fellow eyes after an equivalent postconversion follow-up of approximately 20 months (mean VA: index eye; 20/70 [0.56 logMAR]; fellow eye, 20/50 [0.40 logMAR]; difference, 8 letters [0.15 logMAR]; 95% CI, 4-11 [0.08-0.22]; P < .001). No difference was detected between the mean number of anti-vascular endothelial growth factor injections received by fellow eyes and index eyes (9.7 vs 10.0 injections, respectively). CONCLUSIONS AND RELEVANCE: This retrospective study suggests that fellow eyes of previously treated patients with nvAMD may achieve better VA than their index eye counterparts after an equivalent amount of follow-up. This may be because the CNV was detected and treated earlier and at a better level of VA, although it is unknown whether the frequent office visits, VA measurements, or optical coherence tomography testing was responsible for the detection at a better level of VA.
引用
- Stem MS, Moinuddin O, Kline N, et al. Outcomes of Anti-Vascular Endothelial Growth Factor Treatment for Choroidal Neovascularization in Fellow Eyes of Previously Treated Patients With Neovascular Age-Related Macular Degeneration. JAMA Ophthalmol. 2018. PMID: 29800991. doi:10.1001/jamaophthalmol.2018.1534
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。